Compensation award — excluded from discretionary-purchase analysis.
Loading…
Traded Dec 18, 2025 · Filed Dec 23, 2025
Incyte's Principal Accounting Officer sold $59K of Incyte shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$58,950
Shares × reported transaction price
51 days after results of Oct 28, 2025, 54 days before results of Feb 10, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $97.31 on Dec 18, 2025, 76% above its 52-week low and 10% below its high, after an 8% drop over the previous 30 trading days
52-week range $55.17 (Apr 10, 2025) to $108.26 (Nov 12, 2025), 79% of the way up, from 250 adjusted closes. 30 trading days earlier: $105.70 on Nov 5, 2025. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
FDA approved Zynyz on Dec 17, 2025, 1 day before this trade.
New use approved (efficacy supplement). Active ingredient: Retifanlimab-Dlwr. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -2.0% | -0.1% | -1.8% |
| 30 days | +4.1% | +0.1% | +4.0% |
| 90 days | -10.4% | -4.7% | -5.6% |
| 180 days | +2.7% | +8.2% | -5.5% |
Past results only. Not a forecast.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
